Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label psilocybin-assisted therapy for treatment-resistant depression
ACTRN12624001343594Phase 2Not yet recruiting
- Sponsor
- GoodMind
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in treatment-resistant depression (TRD), sponsored by GoodMind. Primary endpoint: Depression symptoms. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ACTRN12624001343594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001343594.